Your browser doesn't support javascript.
loading
'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.
Rathor, Amber; Malik, Prabhat Singh; Tanwar, Pranay; Khurana, Sachin; Baskarane, Hemavathi; Pushpam, Deepam; Nambirajan, Aruna; Jain, Deepali.
Afiliación
  • Rathor A; Department of Pathology, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Malik PS; Department of Medical Oncology, Dr.B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Tanwar P; Department of Laboratory Oncology, Dr.B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Khurana S; Department of Medical Oncology, Dr.B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Baskarane H; Department of Medical Oncology, Dr.B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Pushpam D; Department of Medical Oncology, Dr.B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Nambirajan A; Department of Pathology, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Jain D; Department of Pathology, All India Institute of Medical Sciences, New Delhi, 110029, India. deepalijain76@aiims.edu.
J Cancer Res Clin Oncol ; 150(7): 371, 2024 Jul 27.
Article en En | MEDLINE | ID: mdl-39066920
ABSTRACT

INTRODUCTION:

The treatment approach for recently diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR mutations primarily relies on confirming the tissue diagnosis as non-squamous NSCLC. This routine clinical practice of tissue diagnosis imposes several barriers and delays in turnaround time (TAT) for biomarker testing, significantly delaying the time to treatment. The objective of this study is to investigate the 'plasma first' approach for detection of EGFR mutation in advanced stage treatment naïve NSCLC patients.

METHODS:

We prospectively collected blood samples of treatment naïve patients with clinical and radiological suspicion of advanced stage NSCLC prior to obtaining tissue biopsy. Plasma cfDNA was tested for EGFR mutation using two different methods. We compared the sensitivity and TAT of liquid biopsy with tissue biopsy.

RESULTS:

In total, we analyzed plasma cell-free DNA (cfDNA) of 236 patients suspected of having advanced NSCLC for EGFR mutations. We observed a notably shorter turnaround time (TAT) of 3 days, which was significantly quicker compared to the 12-day TAT for tissue biopsy (p < 0.05). The ddPCR method had a sensitivity of 82.8%, which was higher than 66.34% sensitivity of ARMS-PCR. The current study also highlights that there is no significant difference in the clinical outcome of the patients whether treated based on liquid biopsy only or tissue biopsy (median progression-free survival of 11.56 vs. 11.9 months; p = 0.94).

CONCLUSIONS:

Utilizing a 'plasma first' strategy, given its shorter turnaround time, strong positive concordance and comparable outcomes to tissue biopsy, emerges as a highly specific and reliable method for detecting EGFR mutations in advanced-stage NSCLC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares / Mutación Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares / Mutación Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Alemania